A detailed history of Woodline Partners LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 125,649 shares of ACLX stock, worth $8.01 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
125,649
Previous 110,989 13.21%
Holding current value
$8.01 Million
Previous $9.27 Million 3.25%
% of portfolio
0.07%
Previous 0.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$75.39 - $106.53 $1.11 Million - $1.56 Million
14,660 Added 13.21%
125,649 $9.57 Million
Q3 2024

Nov 14, 2024

BUY
$50.91 - $86.61 $167,493 - $284,946
3,290 Added 3.05%
110,989 $9.27 Million
Q2 2024

Aug 14, 2024

BUY
$49.74 - $66.98 $181,003 - $243,740
3,639 Added 3.5%
107,699 $5.94 Million
Q4 2023

Feb 14, 2024

BUY
$31.75 - $57.99 $3.3 Million - $6.03 Million
104,060 New
104,060 $5.78 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $2.79B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.